Printer Friendly

IGI Laboratories unveils US FDA approved nonsteroidal anti-inflammatory drug Diclofenac Sodium 1.5%.

M2 EQUITYBITES-July 10, 2015-IGI Laboratories unveils US FDA approved nonsteroidal anti-inflammatory drug Diclofenac Sodium 1.5%

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Pharmaceutical company IGI Laboratories (NYSE MKT:IG) revealed on Thursday the availability of its diclofenac sodium 1.5% topical solution in the US market.

This market launch follows the final approval from the US Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The ANDA to the US FDA was originally filed in December 2010.

According to the company, it now markets seven products in 12 presentations in an IGI label.

The company added that the Diclofenac sodium topical solution 1.5% is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain from osteoarthritis of the knee.

Based on IMS Health data for May 2015, the total addressable market for this product is approximately USD13.3m, concluded the company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 10, 2015
Words:159
Previous Article:Anthera Pharmaceuticals prices public offering at USD7.50 per share.
Next Article:Pembina Pipeline announces dividend of USD0.1525 per share for July and preferred stock dividends for quarter.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters